Heart India

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 9  |  Issue : 3  |  Page : 179--183

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study


Pankaj Jariwala1, Arshad Punjani2, Harikishan Boorugu2, Dilip Babu Madhawar3, Kartik Jadhav1 
1 Department of Cardiology, Yashoda Hospitals, Hyderabad, Telangana, India
2 Department of Internal Medicine, Yashoda Hospitals, Hyderabad, Telangana, India
3 Department of Nephrology and Transplant Medicine, Yashoda Hospitals, Hyderabad, Telangana, India

Correspondence Address:
Dr. Pankaj Jariwala
Department of Cardiology, Yashoda Hospitals, Somajiguda, Raj Bhavan Road, Hyderabad - 500 082, Telangana
India

Background: The goal of this study is to look at the safety and efficacy of angiotensin receptor-neprilysin inhibitors (ARNI) (valsartan/sacubitril), a combination of angiotensin II receptor blocker and neprilysin inhibitor ARNI, in patients with heart failure with preserved ejection fraction (HFpEF). Materials and Methods: Between June and December 2020, retrospective research was conducted on a study participant of primarily angiographically confirmed computer-aided design patients who underwent complete revascularization. A total of 154 HFpEF patients (87 females and 67 males) were treated with ARNI, which was subsequently titrated up to a maximum tolerable dose and monitored in an outpatient clinic. Fifty-six patients were given ARNI while in the hospital for decompensated heart failure before being discharged. Results: Patients were categorized as the New York Heart Association (NYHA) class III (71.4%) and NYHA class II (28.6%). Diabetes mellitus was identified in 52% of patients, while hypertension was found in 78%. Symptomatic clinical improvement was observed, with a substantial decrease in NYHA class down to NYHA class II (P = 0.018). A considerable decrease in NYHA class resulted in symptomatic clinical improvement as well as the rales and peripheral edema had resolved (P < 0.001). The NT-pro-BNP levels were considerably lowered (P < 0.001). The echocardiographic parameters for diastolic function (E/A, E/E' ratios) improved. In individuals with HFpEF, ARNI resulted in significant clinical benefits. Conclusion: In individuals with HFpEF, sacubitril/valsartan, ARNI resulted in significant clinical benefits. A randomized research is also required to see if it results in beneficial outcomes for a wider sample.


How to cite this article:
Jariwala P, Punjani A, Boorugu H, Madhawar DB, Jadhav K. Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study.Heart India 2021;9:179-183


How to cite this URL:
Jariwala P, Punjani A, Boorugu H, Madhawar DB, Jadhav K. Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study. Heart India [serial online] 2021 [cited 2022 May 16 ];9:179-183
Available from: https://www.heartindia.net/article.asp?issn=2321-449x;year=2021;volume=9;issue=3;spage=179;epage=183;aulast=Jariwala;type=0